Bluebee Appoints Two Independent Board Members

Monday, May 8, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

BOSTON and RIJSWIJK, Netherlands, May 8, 2017 /PRNewswire/ --

Bluebee Holding BV,

a leading provider of high performance genomics solutions, today announced the appointment of two new members to its Board of Directors. Lars Kongsbak has been appointed as an independent director, and Nicolas
Roelofs
will become Chairman of the Board.

About Nicolas H Roelofs 

An Industrial Advisor with Nordic Capital LTD, he has gained significant experience from the life science industries over the last 30 years especially in international business.

Previously he was at Agilent Technologies Inc. Life Sciences Group where, as President, he realized a number of acquisitions, including that of Dako. He oversaw the restructuring of the company and was responsible for delivering organic company growth well above the market average.

"Bluebee is at a special point in its development both as a business and as an organization," said Nicolas Roelofs. "I look forward to contributing to the future direction and growth of Bluebee, using my knowledge and past experiences. I am particularly excited that Hans and the team share my passion for building a successful and positive culture." 

About Lars Kongsbak 

Involved with several life science companies where Lars has strong skills and a proven track record in drafting strategies, based on customer, market and technology inputs, and improving profitability. He has gained significant experience, including as Chairman of the Board of Directors of Virogates A/S and as CEO and President of Exiqon A/S. He has been responsible for efficient international commercialization and company growth, a successful IPO and many out-licensing deals.

"There is a strong need in the market for a secure platform for genetic analysis and easy retrieval of raw and analyzed genetic data. This is not served well today and I strongly believe that Bluebee can make a difference in this market," said Lars Kongsbak. "Also, the strategy of serving the end-users through third parties is brilliant, secure cloud solutions, as mentioned above, are not trivial and outsourcing to specialists like Bluebee allows the focus to stay on understanding the samples."? 

These appointments complement Bluebee's Board of Directors with past accomplishments clearly demonstrating the considerable creative negotiation skills and innovative approach.

"We conducted an exhaustive search for people who would further strengthen our board's breadth of talent and background, and we are delighted to have identified such outstanding individuals," said Hans Cobben CEO of Bluebee. "Both Nick Roelofs and Lars Kongsbak will bring a unique perspective and tremendous depth of experience and knowledge, especially in building a global business across both developed and emerging markets." 

ABOUT BLUEBEE  

Bluebee (http://www.bluebee.com) provides high performance genomics solutions, enabling genomic labs to substantially reduce cost and time-to-diagnosis. Bluebee's unique cloud-based accelerated genomics platform enables fast, efficient and affordable processing of large volumes of genomics data. With Bluebee's private-cloud based solutions, labs can run their pipelines orders of magnitude faster without compromising the algorithms and methods used, nor the flexibility required to provide quality, sensitivity and reliability.

The combination of domain experts in the development and deployment of large scale, mission-critical infrastructure, seasoned bioinformaticians and renowned academic researchers in high-performance computing, led to the use of three disruptive technologies - high performance computing, cloud computing and genomics - which together deliver a unique genome analytics service for research and clinical labs.

Bluebee Laan van Zuid Hoorn 57 2289 DC Rijswijk The Netherlands

Bluebee Corp 745 Atlantic Avenue Boston, MA 02111 United States

SOURCE Bluebee



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook